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http://dx.doi.org/10.1016/j.jfma.201Background/purpose: Chronic hepatitis C virus (HCV) infection is a major cause of morbidity
and mortality in patients with hemophilia. However, the efficacy and safety of pegylated inter-
feron (PEG-IFN) plus ribavirin (RBV) for hemophilic patients with chronic HCV infection in
Taiwan are still unknown. The aim of this study is to report the efficacy and safety of PEG-
IFN plus RBV in a single center in Taiwan.
Methods: In an open-label single-treatment one-arm cohort study, 12 hemophilic patients with
elevated alanine aminotransferase level more than two times the upper limit of normal for
m o r e t h a n 3 mo n t h s r e c e i v e d 1 8 0 m g /we e k o f P EG - I F N - a - 2 a p l u s R B V
1000e1200 mg/day at a cut-off value of 75 kg. The duration of treatment was 48 weeks for
patients with HCV Genotype 1/4 infection and 24 weeks for patients with HCV Genotype 2/3
infection. Efficacy of therapy was expressed as sustained virological response (SVR).ave no conflicts of interest relevant to this article.
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728 J.-A. Lin et al.Results: Eight patients achieved SVR (66.7%). The SVR rates were 57%, 100%, 100%, and 0% for
patients with HCV Genotypes 1, 2, 3, and 4 infection, respectively. Adverse events (AEs) devel-
oped in 10 patients (83.3%). Severe thrombocytopenia developed in one patient. However, the
patient did not suffer from severe bleeding.
Conclusion: Our study shows that the SVR rates are similar in hemophilic and nonhemophilic
patients with chronic HCV infection who receive PEG-IFN-a-2a plus RBV in Taiwan. The rate
of AEs also resembled other studies in nonhemophilic patients in Taiwan. No patient suffered
from severe bleeding. However, large-scale, well-conducted studies are still needed to verify
the treatment efficacy and safety.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
People with hemophilia nonvirucidally receiving clotting
factor replacement therapy were at very high risk of
infection with hepatitis C virus (HCV) before the introduc-
tion of donor screening and virus inactivation in the mid-
1980s.1,2 Afterward, advancement in new technologies for
blood products processing has significantly reduced the
prevalence of HCV infection among these patients. At
present, the HCV prevalence rate among hemophilia pa-
tients varies in different parts of the world. In one epide-
miologic study in Taiwan, the prevalence of HCV among
hemophilia patients was approximately 90% in 1990.3
Chronic HCV infection is a major cause of morbidity and
mortality in patients with hemophilia.4 Potential adverse
outcomes of chronic HCV infection are hepatic failure,
cirrhosis, and hepatocellular carcinoma (HCC). Antiviral
therapy plays an important role in the management of HCV-
infected patients. Combination therapy with pegylated
interferon (PEG-IFN) and ribavirin (RBV) can yield sustained
viral eradication in 30e60% of hemophilia cases.5 Achieving
a sustained virological response (SVR) reduces the risk of
hepatic fibrosis progression, hepatic failure, and HCC, and
the need for liver transplantation. The overall SVR rates in
general HCV-infected population receiving PEG-IFN plus
RBV range from 50% to 60%, which is similar to the range in
HCV-infected hemophilic patients.6e9
To our knowledge, the efficacy and safety data regarding
the treatment of HCV-infected hemophiliacs in Taiwan are
still lacking. Therefore, we aimed to evaluate the efficacy
and safety in hemophilic patients with chronic HCV infec-
tion who received combination therapy of PEG-IFN plus RBV
in one medical center.Materials and methods
Patient selection
We had 178 hemophiliacs who were regularly followed up in
the hemophilia center at the Tri-Service General Hospital.
A total of 88 patients (49.4%) were detected with anti-HCV
(determined using VITROS ECi; Ortho Clinical Diagnostics).
There were 39 patients (44.3%) with HCV RNA [determined
using real-time reverse transcriptase polymerase chain re-
action (RT-PCR) analysis, COBAS TaqMan 48, version 1.0;
Roche Diagnostics] for more than 6 months. Among these 39
patients, 12 patients who had elevated levels of alanineaminotransferase (ALT) more than two times the upper
limit of normal for more than 3 months were eligible for this
study (Fig. 1). They were all treatment naı¨ve, aged greater
than 18 years, male, and hemophilia A patients.
Our exclusion criteria were patients with HBV or human
immunodeficiency virus co-infection, decompensated liver
disease, inherent liver disease, cirrhosis, liver transplant,
HCC, poorly controlled psychiatric disease, malignant
neoplastic disease, creatinine clearance <50 mL/minute,
poorly controlled diabetes, severe heart disease, chronic
pulmonary disease, active substance abuse, or autoimmune
disease.Study design
This study was designed as a prospective, single-center,
open-label one-arm treatment study of PEG-IFN-a-2a
(PEGASYS; Roche, Basel, Switzerland) and weight-based
RBV (Rebetol, Schering, Memphis, TN) combination therapy
for chronic HCV infection in hemophiliacs. The study was
conducted from November 2009 to August 2012 at the Tri-
Service General Hospital. The eligible patients received
weekly subcutaneous injections of 180 mg of PEG-IFN-a-2a
plus oral RBV (RBV dose Z 1000 mg/day for patients who
weighed <75 kg and 1200 mg/day for patients who weighed
75 kg). The treatment duration was 48 weeks for patients
with HCV Genotype 1/4 infection and 24 weeks for patients
with HCV Genotype 2/3 infection. Compliance with the
PEG-IFN-a-2a treatment was monitored at the outpatient
department. Routine laboratory test results including
complete blood cell count and serum ALT level, pro-
thrombin time, serum albumin level, bilirubin level, and
creatinine level were assessed at enrollment and at each
following outpatient visit every 4 weeks until the end of the
follow-up period. Serum HCV-RNA levels were quantita-
tively evaluated by RT-PCR analysis (COBAS TaqMan 48,
version 1.0; Roche Diagnostics, limit of detection: 15 IU/
mL) at baseline, week 4, week 12, week 24, week 48, and
24 weeks after the end of treatment. The HCV genotyping
was performed at baseline by a reverse hybridization
technique (INNO-LiPA HCV II; Innogenetics). Liver biopsies
were not performed because of risk of bleeding. The pro-
tocol was approved by the Ethical Committee and was
conducted in accordance with the principles of Declaration
of Helsinki and the International Conference on Harmoni-
zation for Good Clinical Practice. Each patient provided
written informed consent before the study.
Figure 1 Flow diagram of the trial. ALT Z alanine aminotransferase; IFN Z interferon; HCV Z hepatitis C virus; HIV Z human
immunodeficiency virus; ETR Z end of treatment response; EVR Z early virological response.
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Our primary efficacy end point was SVR, defined as unde-
tectable HCV RNA after 24 weeks of untreated follow-up.
Our secondary efficacy end points were rapid viral response
(RVR: negative HCV RNA after 4 weeks of treatment), early
viral response (EVR: greater than 2-log reduction of HCV
RNA at week 12 of treatment compared with the baseline
level by a quantitative HCV-RNA assay), and end of treat-
ment response (ETR: negative HCV RNA at the end of thetreatment). According to the established guidelines, pa-
tients who did not achieve EVR or ETR were considered as
treatment failure, and were therefore withdrawn from the
treatment.
Assessment of safety
Before commencing combination therapy, baseline liver
biochemical test levels and a complete blood count were
obtained. Participants were evaluated for adverse events
Table 1 Baseline characteristics of hemophilia patients
infected with HCV who received therapy with pegylated
interferon alfa-2a plus ribavirin.
Characteristic n Z 12
Age, mean years  SD 45.3  11
Male sex, n (%) 12 (100)
Mean body mass index, kg/m2  SD 23.9  4.5
Hemoglobin level, mean g/dL  SD 15.0  1.5
WBC count, mean  cells/mm3  SD 4.2  1.6
Platelet count, mean  cells/mm3  SD 148  53
AST, IU/L  SD 69.2  41.0
ALT, IU/L  SD 116.6  57
Genotype
1 7 (58)
2 2 (17)
3 2 (17)
4 1 (8)
Data are number (%) of patients, unless otherwise indicated.
ALT Z alanine aminotransferase; AST Z aspartate amino-
transferase; HCVZ hepatitis C virus; SDZ standard deviation;
WBC Z white blood cell.
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department to assess safety. Participants were considered
withdrawn from the study if the safety was concerned or
AEs cannot be tolerated. Patients who withdrew from the
study were encouraged to receive outpatient visits without
treatment until the end of the follow-up period. The dose
of PEG-IFN-a-2a was reduced to 90 mg/week if the neutro-
phil count was 500e750 cells/mm3 or platelets count was
30,000e50,000 cells/mm3. Decline of the neutrophil count
to below 500 cells/mm3, decline of the platelet count to
below 30,000 cells/mm3, and decline of hemoglobin levels
to below 7 g/dL (because of lack of tolerance) were also
considered as criteria for PEG-IFN discontinuation. The RBV
dose was stepwise reduced to 200 mg/week when the he-
moglobin level declined to below 10 g/dL and was dis-
continued when it declined to below 8.5 g/dL.Table 2 Treatment response rate of hemophilia patients infect
Genotype 1 Ge
Viral responses (n/N, %)
RVR 2/7 (29) 2/2
EVR 5/7 (71) 2/2
ETR 5/7 (71) 2/2
SVR 4/7 (57) 2/2
Non-SVR 3/7 (43) 0/2
Relapse 1/7 (14) 0/2
Viral breakthrough 0/7 (0) 0/2
Null response 2/7 (29) 0/2
Missing 0/7 (0) 0/2
ETRZ end of treatment response (negative HCV RNA at the end of the
reduction of HCV RNA at week 12 of treatment compared with the
response (negative HCV RNA after 4 weeks of treatment); SVRZ susta
after the end of therapy).Hematological support factors were used when required.
Recombinant human granulocyte-colony stimulating factor
(G-CSF) was administered if the neutrophil count was below
500 cells/mm3. Neutrophil count was checked subsequently
at weekly intervals and G-CSF was administered further if
necessary in cases where the neutrophil count did not in-
crease satisfactorily. If the hemoglobin level continues to
decline despite reduction in RBV dose, that is, to levels
<10 g/dL, erythropoietin treatment was permitted. We did
not perform blood transfusion to correct anemia and
thrombocytopenia to meet the study design requirements.
Whenever the patients had an abnormal laboratory test
result, in addition to dose adjustment, they were asked to
recheck that laboratory test at 1-week intervals until it
became normal. Otherwise, the treatment was dis-
continued permanently. If the laboratory abnormalities and
the severity of AEs improved or resolved after dose reduc-
tion or treatment cessation, a return to the initial dose was
permitted.
Statistical analyses
Patient characteristics were expressed as mean  standard
deviation and percentages as appropriate. Characteristics
were compared by c2 test, Fisher exact test, or Student t
tests when appropriate. Intention-to-treat analyses for the
primary efficacy and safety end points were performed for
patients who received treatment. Summary statistics for
virological outcome are reported in the form of percentage
for subgroups of patients defined by their genotype.
Results
Virological response rates and treatment regimen
efficacy
Table 1 shows the illustrates the baseline characteristics of
the 12 patients. Table 2 shows the results of therapy. A
total of eight patients who constituted 53% of all patients
achieved SVR. Genotype 1 had the lowest SVR (51.7%)ed with HCV.
notype 2 Genotype 3 Genotype 4
(100) 2/2 (100) 0/1 (0)
(100) 2/2 (100) 0/1 (0)
(100) 2/2 (100) 0/1 (0)
(100) 2/2 (100) 0/1 (0)
(0) 0/2 (0) 0/1 (0)
(0) 0/2 (0) 0/1 (0)
(0) 0/2 (0) 0/1 (0)
(0) 0/2 (0) 1/1 (100)
(0) 0/2 (0) 0/1 (0)
treatment); EVRZ early virologic response (a greater than 2-log
baseline level); HCV Z hepatitis C virus; RVR Z rapid virologic
ined virologic response (undetectable HCV-RNA levels at 24 weeks
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100% 100%100% 100%100%100%
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Figure 2 Virologic response rate (%) according to rapid viral
response (RVR), end of treatment response (ETR), and sus-
tained virological response (SVR).
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One patient in Genotype 4 did not respond at all.
One patient (7%) relapsed during 24 weeks of untreated
period. Two patients (16.7%) did not respond at all. One
patient (7%) suffered from treatment failure. Fig. 2 shows
the virological response through treatment duration and 24
weeks of untreated follow-up. As shown, the viral kinetics
were similar among these four groups of patients during
treatment.Table 3 Incidence of AEs, premature withdrawals, and
dose modifications.
AEs Frequencies of AEs,
n/N (%)
Headache 1/12 (8%)
Insomnia 1/12 (8%)
Fatigue 2/12 (17%)
Flu-like symptoms 1/12 (8%)
Myalgia 1/12 (8%)
Cough 2/12 (17%)
Pruritus 4/12 (33%)
Laboratory AEs
Anemia (<10 g/dL) 2/12 (17%)
Neutropenia
(<750 cells/mm3)
2/12 (17%)
Thrombocytopenia
(<50,000 cells/mm3)
1/12 (8%)
Serious adverse eventsa
All 0/12 (0%)
Death 0/12 (0%)
Treatment related 0/12 (0%)
Treatment withdrawal due
to adverse events
1/12 (8%)
Dose reduction due to
adverse events
Peginterferon 2/12 (17%)
Ribavirin 2/12 (17%)
AEs Z adverse events.
a Serious adverse events were hepatic decompensation, major
depression, sepsis, severe bleeding, pulmonary tuberculosis,
hepatocellular carcinoma.AEs
AEs were reported in 10 patients (83%), and most of them
were considered to be related to the treatment (Table 3).
Pruritus was the most common AE, which occurred in four
patients (33%). One patient (8%) discontinued treatment
due to sever fatigue. Two patients (17%) received erythro-
poietin due to anemia (<10 g/dL) and needed dose reduc-
tion of RBV. Two patients (17%) had dose reduction of PEG-
IFN due to neutropenia (<500 cells/mm3). One patient (8%)
had severe thrombocytopenia (<20,000 cells/mm3) and
thus PEG-IFN treatment was discontinued in the patient.
However, the patient did not suffer from severe bleeding.
No increase in bleeding episodes or more frequent use of
clotting factor was reported in any other patient.Discussion
In one epidemiologic study in Taiwan, the prevalence of
HCV among hemophilia patients was approximately 90% in
1990.3 The higher rate of chronic HCV infection in hemo-
philic patients in Taiwan may be reasoned by HCV trans-
mitted mainly by the parenteral route in Taiwan.10
Although accumulating evidence indicates that PEG-IFN-a-
2a and RBV can successfully treat patients with hemophilia
infected with hepatitis C, the safety and efficacy of dual
combination therapy for chronic HCV infection in the he-
mophilic patients are still unknown in Taiwan. In our study,
the prevalence rate of HCV among hemophilia patients was
49.4%. A total of 39 patients (44.3%) were detected with
HCV RNA. From the literature, approximately 15e25% of
adult patients who acquired post-transfusion HCV cleared
their infection.11 In our study, 55.7% have presumably
cleared HCV infection. This rate is higher than other
studies, in which 27% of hemophilia patients were shown to
naturally clear HCV infection.12
Our study showed that HCV Genotype 1 infection pre-
dominated in hemophilic patients (59%). The PEG-IFN plus
RBV therapy achieved an SVR of 51.7% in Genotype 1, and
the treatment efficacy of Genotypes 2 and 3 achieved an
SVR of 100%. The response rate of treatment in patients
without hemophilia infected with HCV was approximately
77% (76e80%) for Genotype 113e16 and 95% for Genotypes 2
and 3 in Taiwan.17,18 The SVR rate in patients with hemo-
philia infected with HCV was 45% for Genotype 1 and 79%
for Genotypes 2 and 3 in Western countries.9 In conclusion,
in our study, the SVR rate in Genotype 1, and Genotype 2/3
was similar to that of the patients without hemophilia
infected with HCV in Taiwan, and better than the patients
with hemophilia infected with HCV in other countries. A
better treatment response in Asian patients has been
noticed. Possible explanations might include different dis-
tribution of host genetic variants such as IL-28B genetic
polymorphisms, HCV quasispecies, and higher dose of RBV
exposure by body weight.19 Among the factors, the IL-28B
genetic polymorphisms might play a determinant role.
The East Asian populations had the higher prevalence of IL-
28B-favorable genotype (rs12979860 or rs8099917), which
accounted for a better treatment response in the Asian
populations.20e22
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have received either no or suboptimal treatment for their
hepatitis.23 The main reasons for the unsatisfactory treat-
ment rate are the fear of unpleasant AEs of antiviral
treatment by the patients and the lack of appreciated ef-
ficacy of antiviral therapy by their physicians.24 The PEG-
IFN and RBV are poorly tolerated due to their AEs, which
include flu-like symptoms, depression, and hematological
toxicity. Managing AEs before complications arise enhances
the chance of full dose of treatment throughout the full
duration of therapy. Neutropenia, anemia, and thrombo-
cytopenia are common reasons for dose reduction or
withdrawal of IFN or PEG-IFN/RBV combination therapy in
clinical trials in HCV. The use of hematological support
prevents the dose reductions of RBV seen in 25% of patients
within the first 2 months.25,26 G-CSF can be used to support
full dose of treatment and duration of treatment when
neutropenia develops during treatment.27,28 Supporting
anemia with erythropoietin has been shown to have a
positive effect on the quality of life.29,30 Eltrombopag, a
platelet growth factor, can be used in patients having a
platelet count of 20,000e30,000 cells/mm3 and in whom no
further PEGeIFNea-2a dose reductions can be made.
However, it is very expensive and difficult to get insurance
approval for. As result, it was not widely used. Our patients
suffered from the AEs during treatment as shown in Table 2
and the overall rate was 91.6%, which is closer to the value
in another study (88%).31 Two patients (17%) suffered from
severe neutropenia (neutrophil count <500 cells/mm3) and
received G-CSF during treatment. One patient (8%) suffered
from thrombocytopenia (<50,000 cells/mm3). However,
the patient did not suffer from severe bleeding, which is
the major concern of AEs in hemophilia patients. Compared
with nonhemophilic patients infected with HCV in Taiwan,
the rate of thrombocytopenia was similar.32 In conclusion,
the treatment with PEG-IFN-a-2a plus RBV for patients with
hemophilia infected with HCV in our study was safe.Conclusion
Our study shows that the SVR rates are similar in hemophilic
and nonhemophilic patients with chronic HCV infection who
receive PEG-IFN-a-2a plus RBV in Taiwan, and better than
the hemophilic patients with HCV infection in other coun-
tries. The rates of AEs resembled other studies. Although
thrombocytopenia occurred during treatment, no severe
bleeding occurred.
The limitations of our study are the following: this is a
small-scale one-arm study. In addition, this is an open-label
nonrandomized study, which may introduce experimenters’
biases. We had no IL-28B genotyping analysis and no
objective assessment of hepatic fibrosis, which may influ-
ence the treatment efficacy. We also did not design a
prespecified checklist for the AEs reported in the form,
which may lose some AEs reported by patients. Neverthe-
less, the number of hemophilia patients with HCV infection
included in our study is too small to adequately address the
efficacy and safety issues. The long-term outcome after
PEG-IFN-a-2a plus RBV therapy remains unclear. Therefore,
large-scale, well-conducted studies are necessary to
answer these interesting and important issues.Acknowledgments
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